A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02662582
- Locations
- 🇺🇸
Site US10001, Torrance, California, United States
🇺🇸Site US10003, Pittsburgh, Pennsylvania, United States
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02639182
- Locations
- 🇺🇸
Site US01026, Tucson, Arizona, United States
🇺🇸Site US01008, La Jolla, California, United States
🇺🇸Site US01007, Los Angeles, California, United States
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: AGS67E
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02610062
- Locations
- 🇺🇸
Site US0006, Duarte, California, United States
🇺🇸Site US0004, New York, New York, United States
🇺🇸Site US0001, Houston, Texas, United States
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT02588261
- Locations
- 🇺🇸
Site US10029, Beverly Hills, California, United States
🇺🇸Site US10025, Fountain Valley, California, United States
🇺🇸Site US10036, La Jolla, California, United States
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02571816
- Locations
- 🇺🇸
Site US10001, Miami, Florida, United States
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
- Conditions
- Advanced Solid TumorsAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02561455
- Locations
- 🇺🇸
Site US10005, Phoenix, Arizona, United States
🇺🇸Site US10003, Baltimore, Maryland, United States
🇺🇸Site US10006, New York, New York, United States
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT02528643
- Locations
- 🇺🇸
Site US10003, San Francisco, California, United States
🇺🇸Site US10009, Skokie, Illinois, United States
🇺🇸Site US10017, Minneapolis, Minnesota, United States
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02495233
- Locations
- 🇯🇵
Site JP81004, Fukuoka Minami-ku, Fukuoka, Japan
🇯🇵Site JP81005, Osakasayama, Osaka, Japan
🇯🇵Site JP81003, Suntogun Nagaizumicho,Shizuoka, Japan
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
- Conditions
- Pharmacokinetics of 14C-labeled GilteritinibAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02456883
- Locations
- 🇺🇸
Site US10001, Cleveland, Ohio, United States
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02441517
- Locations
- 🇺🇸
Site US10003, Evanston, Illinois, United States
🇺🇸Site US10006, Worcester, Massachusetts, United States
🇺🇸Site US10004, New York, New York, United States